newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded